Catálogo de publicaciones

This book covers our current understanding of the role of mesenchymal stem cells (MSCs) and other mesenchymal progenitors in skeletal regeneration, encompassing bone, cartilage and whole joint regeneration. The expansion reflects developments in the field to include data on the use of MSCs in drug development, growth factors, scaffolds and biomechanical manipulations for skeletal trauma and diseases, including osteoporosis and arthritis.

Written for an audience of clinicians and young researchers who are exposed to MSCs in their work, this work summarizes recent findings pertaining to the definition and characterization of MSCs in skeletal tissues and discusses the mechanisms of their actions in regeneration of bone in vivo. The authors describe recent findings pertaining to the efficacy of MSC therapies in animal models and in human clinical trials and bring together literature showing that the ways MSCs are extracted, expanded and implanted can considerably affect bone formation outcomes. Finally, it presents the latest knowledge on the nature of native MSCs in skeletal tissues, which provide a platform for novel in situ tissue regeneration approaches for systemic bone disease such as osteoporosis.

• Focuses specifically on the use of stem cells in skeletal tissue generation for a broad audience of stem cell, cancer, and bone biologists, orthopedists, oncologists, and regenerative medicine specialists
• Provides a short historical ‘detour’ and foundational information on founding concepts, discoveries and personalities in MSC research
• Assists a new generation of scientists and clinicians in digesting the multitude of journal articles on the topic by providing easily-absorbed and condensed foundational context

With the thorough understanding of stem cell biology and the advent of targeted therapeutics for cancer, stem cell-based therapeutic strategies are being increasingly explored for the treatment of various cancer types. Mesenchymal Stem Cells in Cancer Therapy sheds light on current stem cell based targeted therapies for cancer, by focusing on the application of mesenchymal stem cells (MSC) in various cancers with emphasis on a number of aspects that are critical to the success of future stem cell based therapies for cancer. Sections of this publication are devoted to developing stem cell based therapies for cancer with the main focus on tumoritrophic properties of stem cells, engineering targeted therapeutics, utilization of imaging techniques and the recent combination studies utilizing currently employed therapeutics with stem cells. Mesenchymal Stem Cells in Cancer Therapy informs readers about critical and cutting edge stem cell therapies for cancer and also enables them to appreciate the vast plain of unresolved questions in stem cell research for cancer therapeutics.

• Includes biological foundation on key sources of mesenchymal stem cells and the various ways they can be utilized to treat cancer.
• Provides examples of current MSC based cancer therapies and prospects for the future with insights from the leading lab on cancer cell therapies.
• Technically advanced topic written for widespread understanding for clinical and research audiences.

Metabolic Inhibitors: A Comprehensive Treatise, Volume II charts the major advances that have been made in understanding metabolic inhibition and inhibitors. The book explores the inhibition of enzymes, such as catechol amines, acetylcholinesterases, and succinic dehydrogenases, as well as inhibitors of processes ranging from gas transport to photosynthesis, nitrogen fixation, nitrification, and oxidative phosphorylation.
Organized into 23 chapters, this volume begins with a discussion on the biosynthesis of nicotinamide adenine dinucleotide and dinucleotide analogues. The reader is then introduced to the biochemical significance and mode of action of antibiotics; substances interfering with the biogenesis and metabolism of catechol amines; and inhibition of enzyme activities by thioarsenites. Some chapters focus on mercaptide-forming agents, biological alkylating agents, organophosphates, and carbamates, while others examine the metabolic inhibitory effects of quinones, fungicides, and surface active agents. The book also considers the effects of anesthetics, depressants, and tranquilizers on cerebral metabolism, and then concludes with a chapter on inhibition caused by radiation.
This book is a valuable resource for biochemists, advanced students, medical research workers, and research workers in the fields of biological chemistry, microbiology, botany, and agriculture.

Metabolic Phenotyping in Personalized and Public Healthcare provides information on the widespread recognition that a personalized or stratified approach to patient treatment may offer a more efficient and effective healthcare solution than phenotype-led approaches.

In order to achieve that objective, a deep personal description is required at the level of the genome, proteome, metabolome, or preferably a combination of these aided by technology. This book, edited and written by the outstanding luminaries of this evolving field, evaluates metabolic profiling and its uses across personalized and population healthcare, while also covering the advent of new technology fields, such as surgical metabonomics.

In addition, the text presents specific examples of where this technology has been used clinically and with efficacy, pointing towards a framework and protocol for usage as it hits the clinical mainstream.

• Translates the conjunction of new surgical tools for intraoperative, real-time, metabolite evaluation and direct analysis of biofluid samples into novel options for augmented clinical decision-making
• Discusses longitudinal sampling from individual patients for stratified medicine
• Covers high resolution analytical spectroscopy and sophisticated computational modelling for prediction of adverse reactions in critical care scenarios, prognostic evaluation of cancer from biofluidism, and prognostic prediction of metabolism or response of patients to pharmaceutical interventions
• Encapsulates recent technology options for broader population profiling considerations, in particular, the metabolome-wide association studies (MWAS) that aid the translational researcher in identifying metabolic patterns associated with disease
• Foreword written by Professor Dame Sally Davies who is the Chief Medical Officer for England